Suzhou Yilian Bio-Pharmaceutical Co Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Suzhou Yilian Bio-Pharmaceutical Co Ltd - overview
Established
2020
Location
-, -, China
Primary Industry
Biotechnology
About
Founded in 2020 by CEO Xue Tongtong and based in China, Suzhou Yilian Bio-Pharmaceutical Co Ltd, also known as Yilian Biotechnology, operates as a biotechnology company that develops antibody conjugated drugs (ADC). The firm raised funding of CNY 350 million in March 2021 from Xingze Capital, Qiming Venture Capital, and Loyal Valley Capital. Yilian Biotechnology develops antibody conjugated drugs to treat cancer cells and release a toxic drug into the cancer cell. The firm plans to use its Series A funds towards the development of its antibody conjugated drug (ADC) product pipeline and the establishment of a new conjugated drug research and development platform.
Current Investors
Qiming Venture Partners, Loyal Valley Capital, Apricot Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.